( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Asia Training Course" has been added to ResearchAndMarkets.com's offering.

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

MORE than a trillion dollars were wiped off some of the world’s biggest tech firms yesterday after markets were blindsided by ...

Stocks across Asia lost ground on Monday as worries about Chinese AI company DeepSeek reverberated. The company's discounted R1 model knocked tech stocks, sending the Nikkei ( ^N225) in Japan 0.9% ...